Jilin Province Huinan Changlong Bio-pharmacy Company Limited (abbreviated as “Jilin Changlong”) reported zero movement in both authorised and issued share capital for the month ended 30 April 2026, according to its latest Monthly Return filed with Hong Kong Exchanges and Clearing Limited on 05 May 2026.

Authorised/Registered Share Capital • H-share tranche: 172.50 million ordinary shares at a par value of RMB 0.1 each, unchanged at RMB 17.25 million. • Domestic tranche: 387.75 million ordinary shares at a par value of RMB 0.1 each, unchanged at RMB 38.78 million. Total authorised/registered capital therefore remained stable at RMB 56.03 million.

Issued Shares and Public Float • Issued H-shares stood at 172.50 million with no treasury shares recorded. • Issued Domestic shares remained at 387.75 million. • The company confirmed compliance with the minimum 25% public-float requirement stipulated by the GEM Listing Rules.

Capital Instruments The filing recorded no outstanding or newly issued share options, warrants, convertibles, or other equity-linked instruments during the reporting period.

The absence of share movements and the maintained compliance with listing requirements signal a steady capital structure for Jilin Changlong through April 2026.